- Home
- PVLA vs GHRS Comparison
PVLA vs GHRS Comparison
Compare PVLA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PVLA | GHRS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 892.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PVLA | GHRS |
|---|---|---|
| Price | $100.91 | $16.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $145.24 | $32.00 |
| AVG Volume (30 Days) | 253.4K | ★ 691.5K |
| Earning Date | 11-11-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.10 | $7.98 |
| 52 Week High | $114.69 | $20.50 |
Technical Indicators
Market Signals| Indicator | PVLA | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 62.29 |
| Support Level | $90.85 | $14.71 |
| Resistance Level | $106.27 | $17.33 |
| Average True Range (ATR) | 8.03 | 1.48 |
| MACD | 0.04 | 0.34 |
| Stochastic Oscillator | 75.89 | 69.42 |
Price Performance
Historical ComparisonAbout PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.